Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
56 pending office actions • 49 clients • 53 examiners • 38 art units • 0 of 56 (0%) have an AI response strategy ready
This profile covers Biotechnology & Pharmaceuticals and has 56 pending office actions. Its career record includes 1055 applications, with a resolved allowance rate of 82.48%. The profile combines a sizable active docket with a substantial historical application record.
The average of 3.92 office actions per allowance indicates the recorded prosecution effort associated with allowed matters. Practitioners can use the allowance rate to evaluate historical outcomes and the office-action average to plan response resources. The pending workload should remain a separate measure of current activity.
Based on the USPTO statutory response window for each pending office action. 20 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 20 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (7%) |
| §103 only | 16 (29%) |
| §112 only | 3 (5%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 5 (9%) |
| Multi-statute (no §101) | 27 (48%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLLEY, CHRISTOPHER M | 2 | 73.0% | +26.2% |
| BEKKER, KELLY JO | 2 | 16.8% | +35.1% |
| BORGEEST, CHRISTINA M | 2 | 55.7% | +21.4% |
| STULII, VERA | 1 | 32.7% | +24.9% |
| DEMEREE, CHRISTOPHER R | 1 | 68.9% | +14.2% |
| VAN KREUNINGEN, KYRA MELOR | 1 | 100.0% | +0.0% |
| WILLIAMS, KEITH RICHARD | 1 | 50.0% | +0.0% |
| GOUGH, TIFFANY MAUREEN | 1 | 31.7% | +46.5% |
| ALAOUIE, ALI MUSTAFA | 1 | — | — |
| MAYHEW, BRADLEY SCOTT | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17905646 | BLOOD PREPARATION USEFUL FOR WOUND HEALING AND TISSUE REGENERATION | MELLER, MICHAEL V | 78d overdue |
| 17904895 | HYBRID COSMETIC PRODUCT CONSISTING OF CREAMY COMPACT POWDER | OLSEN, KAELEIGH ELIZABETH | 78d overdue |
| 18040525 | RETANNING AND FATLIQUORING COMPOSITIONS COMPRISING A HEMP OIL DERIVATIVE | KHAN, AMINA S | 46d overdue |
| 17367666 | USE OF NEGATIVE FUNCTIONAL MODULATORS OF ERYTHROPOIETIN FOR THERAPY | DEBERRY, REGINA M | 46d overdue |
| 17609416 | FERTILIZING COMPOSITION COMPRISING A GLASS MATRIX | SILVA RAINBOW, HEATHER ELISE | 42d overdue |
| 18246607 | RECOMBINANT YEAST FOR THE PRODUCTION OF OLIGOPEPTIDE | NOAKES, SUZANNE MARIE | 18d overdue |
| 17756908 | NEW STRAINS OF LACTIC ACID BACTERIA, FOOD COMPOSITION COMPRISING THEM, PREPARATION OF SUCH COMPOSITION | DAVIS, RUTH A | 5d overdue |
| 17798218 | BIO-BASED BINDERS AND METHODS FOR PRODUCING SAME | TOLIN, MICHAEL A | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18561818 | FILLER FOR POLYMERIC COMPOSITIONS DERIVED FROM CITRUS PROCESSING AND/OR PRESSING WASTE | POLLEY, CHRISTOPHER M | 61d |
| 19073256 | HYDROLYSIS OF BREWER'S SPENT GRAIN | STULII, VERA | — |
| 19053630 | WATER-BASED INKS FOR DIGITAL PRINTING ON EDGES | POLLEY, CHRISTOPHER M | — |
| 19103673 | PACKAGE FOR COMESTIBLE | DEMEREE, CHRISTOPHER R | — |
| 18865784 | LACTICASEIBACILLUS PARACASEI DG(R) CNCM I-1572 DSM 34154 FOR USE IN A METHOD OF TREATING DYSBIOSIS IN PATIENTS WITH IBS | GOUGH, TIFFANY MAUREEN | — |
| 18863428 | CONFECTIONERY PRODUCT RESISTANT TO HIGH TEMPERATURES | BEKKER, KELLY JO | — |
| 18702344 | ANTIBODIES DIRECTED AGAINST ALPHA-FOLATE RECEPTOR | BORGEEST, CHRISTINA M | — |
| 18687442 | METHOD FOR INCORPORATING FAT-SOLUBLE INGREDIENT INTO COMESTIBLE PRODUCT, AND PRODUCT RESULTING THEREFROM | BEKKER, KELLY JO | — |
| Art Unit | Apps |
|---|---|
| 1792 | 4 |
| 1651 | 3 |
| 1613 | 3 |
| 1693 | 3 |
| 1656 | 3 |
| 1785 | 2 |
| 1614 | 2 |
| 1675 | 2 |
| 1629 | 2 |
| 1623 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19073256 | HYDROLYSIS OF BREWER'S SPENT GRAIN | Heallo S.r.l. | STULII, VERA | 1791 | §103§112 | Non-Final OA | — | Pending | Mar 07, 2025 |
| 19053630 | WATER-BASED INKS FOR DIGITAL PRINTING ON EDGES | Inkgenio S.R.L | POLLEY, CHRISTOPHER M | 1785 | §102§103 | Non-Final OA | — | Pending | Feb 14, 2025 |
| 19103673 | PACKAGE FOR COMESTIBLE | Perfetti Van Melle Benelux BV | DEMEREE, CHRISTOPHER R | 3734 | §102§103 | Non-Final OA | — | Pending | Feb 13, 2025 |
| 19101414 | NON-AQUEOUS UV/LED DIGITAL INKS FOR PRINTING FLEXIBILE MATERIALS | Engler Italia S.r.l. | VAN KREUNINGEN, KYRA MELOR | 2853 | §103§112 | Non-Final OA | — | Pending | Feb 05, 2025 |
| 18868253 | SOYBEAN PLANT CHARACTERIZED BY HIGH DROUGHT RESISTANCE | Sipcam Oxon S.p.A. | WILLIAMS, KEITH RICHARD | 1663 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18865784 | LACTICASEIBACILLUS PARACASEI DG(R) CNCM I-1572 DSM 34154 FOR USE IN A METHOD OF TREATING DYSBIOSIS IN PATIENTS WITH IBS | Alfasigma S.p.A. | GOUGH, TIFFANY MAUREEN | 1651 | §102§112DP | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18863428 | CONFECTIONERY PRODUCT RESISTANT TO HIGH TEMPERATURES | Perfetti Van Melle S.p.A. | BEKKER, KELLY JO | 1792 | §103§112 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18849545 | TOPICAL PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY AND USES THEREOF | Glycores 2000 Srl | ALAOUIE, ALI MUSTAFA | 1614 | §103§112 | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18841688 | COMPOSITIONS COMPRISING BUTYRIC ACID AND GLUCONIC ACID FOR THE TREATMENT OF DISORDERS AND SYNDROMES ASSOCIATED WITH INTESTINAL BARRIER DYSFUNCTIONS AND DYSBIOSIS | Difass International S.p.A. | MAYHEW, BRADLEY SCOTT | 1621 | §103 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18840081 | A PROCESS FOR THE PRODUCTION OF A SOYBEAN FLOUR HAVING A HIGH SOLUBILITY | La Sanfermese S.p.A. | LEFF, STEVEN N | 1792 | §103 | Final Rejection | — | Pending | Aug 21, 2024 |
| 18835362 | QUERCETIN-BASED COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF OCULAR AFFECTIONS | Indena S.p.A. | RAO, SAVITHA M | 1691 | §103DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18832515 | COMPOSITION CONTAINING NERO DI TROIA POMACE EXTRACT | Planbio Cosmetics Srl | HOLT, ANDRIAE M | 1614 | §103§112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18721678 | METHOD FOR THE PREPARATION OF HYBRID POLYMERIC NANOPARTICLES FOR THE RELEASE OF OLIGONUCLEOTIDE DRUGS IN PHARMACOLOGICAL THERAPIES FOR REGENERATIVE, CURATIVE, AND PREVENTIVE PURPOSES | UNIVERSITA' DEGLI STUDI DI TORINO | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | — | Pending | Jun 19, 2024 |
| 18719160 | PROBIOTIC COMPOSITIONS AND THEIR USE IN MODULATING ALLERGY-TYPE INFLAMMATORY ACTIVITY | Synbalance Srl | CELSA, BENNETT M | 1651 | §103§112 | Final Rejection | 20d | Pending | Jun 12, 2024 |
| 18675187 | STABLE GEL FORMULATIONS FOR THE TREATMENT OF ACNE VULGARIS | BIOSEUTICA B.V. | FERNANDEZ, SUSAN EMILY | 1651 | §101§103§112 | Final Rejection | — | Pending | May 28, 2024 |
| 18666909 | LENTIL PASTA AND METHOD FOR ITS PREPARATION | Andriani S.p.A. | O'HERN, BRENT T | 1793 | §103 | Non-Final OA | — | Pending | May 17, 2024 |
| 18709841 | LIQUID COMPOSITION OF CERAMIDES AND PALMITIC ACID AMIDES | Unifarco S.p.A. | BAZARGANI, ARYA AHMADI | 1613 | §101§102§103§112 | Final Rejection | — | Pending | May 14, 2024 |
| 18703377 | IMPROVED PROCESS FOR PROCESSING BIOLOGICAL SAMPLES | Diapath S.p.A. | SIMMONS, VALERIE MICHELLE | 1758 | §103§112 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18702344 | ANTIBODIES DIRECTED AGAINST ALPHA-FOLATE RECEPTOR | Fondazione Irccs Istituto Nazionale Dei Tumori | BORGEEST, CHRISTINA M | 1675 | §102§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18701691 | EXTRACELLULAR VESICLES DERIVED FROM MILK AND PROCESS FOR ISOLATING THE SAME | Evobiotix SA | STEVENS, MARK V | 1613 | §103§112 | Final Rejection | — | Pending | Apr 16, 2024 |
| 18700010 | DETERGENT COMPOSITION FOR INTERNAL PARTS OF VEHICLES | Ma-Fra S.p.A. | GOLIGHTLY, ERIC WAYNE | 1714 | §103 | Final Rejection | 26d overdue | Pending | Apr 10, 2024 |
| 18695504 | PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES | Indena S.p.A. | KOSAR, ANDREW D | 1625 | §103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18616250 | METHYLENE BLUE HAVING A REDUCED CONTENT OF N-NITROSO-AZURE B IMPURITY AND PROCESS FOR OBTAINING THE SAME | Icrom S.r.l. | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | DP | Final Rejection | — | Pending | Mar 26, 2024 |
| 18596842 | POLYAMINOMETHYLENE PHOSPHONATE DERIVATIVES WITH LOW PHOSPHOROUS CONTENT HAVING SEQUESTERING AND DISPERSING PROPERTIES, RELATED USES AND PROCESSES FOR THE PREPARATION THEREOF | Giovanni Bozzetto S.p.A. | RHOADES, DEREK JAMES | 1692 | §102§103§112 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18687442 | METHOD FOR INCORPORATING FAT-SOLUBLE INGREDIENT INTO COMESTIBLE PRODUCT, AND PRODUCT RESULTING THEREFROM | Perfetti Van Melle Benelux BV | BEKKER, KELLY JO | 1792 | §102§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18681534 | BIOMIMETIC PEPTIDES AND THEIR USE IN BONE REGENERATION | Silk Biomaterials S.r.l. | BORGEEST, CHRISTINA M | 1675 | §101§112 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18681188 | PLATELETS TRANSFECTED WITH SIRNA AND THE THERAPEUTICS USES THEREOF | Plasfer S.r.l. | LIPPOLIS, ALEXANDRA ROSE | 1653 | §103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18290888 | PHARMACEUTICAL OR FODD SUPPLEMENT FORMULATION CONTAINING ALPHA-LACTALBUMIN AND BUTYRIC ACID OR A SALT THEREOF | Kolfarma S.r.l. | TRUONG, QUANGLONG N | 1615 | §103 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18580851 | PROCESSES FOR THE PREPARATION OF ESTETROL AND INTERMEDIATES THEREOF | Newchem S.p.A. | CHENG, KAREN | 1623 | §112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18579109 | METHOD FOR EVALUATING RESIDUAL PLATELET THROMBOTIC POTENTIAL IN PATIENTS UNDERGOING ANTIPLATELET TREATMENT | UNIVERSITA' DEGLI STUDI DI MILANO | WALLENHORST, MAUREEN | 1797 | §101§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18579158 | USE OF LACTOBACILLUS PARACASEI BACTERIAL STRAINS IN THE TREATMENT OF NEWBORNS | Alfasigma S.p.A. | CHHAY, BONIRATH | 1645 | §103§112DP | Final Rejection | 2d overdue | Pending | Jan 12, 2024 |
| 18577782 | A PROCESS FOR THE PRODUCTION OF AMCIPATRICIN DIASCORBATE AND THE USE OF THE SAME FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS RESISTANT TO TRADITIONAL ANTIFUNGAL AGENTS | BIOSEUTICA B.V. | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18577345 | NEW SYSTEMS FOR PRODUCING RECOMBINANT PROTEINS | Nemysis Limited | CHOWDHURY, IQBAL HOSSAIN | 1656 | §112Other | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18565715 | OILY FORMULATIONS OF CANNABINOIDS | VELLEJA RESEARCH S.R.L. | BOECKELMAN, JACOB A | 1655 | §103 | Final Rejection | — | Pending | Nov 30, 2023 |
| 18561818 | FILLER FOR POLYMERIC COMPOSITIONS DERIVED FROM CITRUS PROCESSING AND/OR PRESSING WASTE | Krill Design Srl | POLLEY, CHRISTOPHER M | 1785 | §103 | Final Rejection | 61d | Pending | Nov 17, 2023 |
| 18560254 | MIXTURES OF POLYSACCHARIDES AND POLYAMINOSACCHARIDES WITH IMPROVED RHEOLOGICAL PROPERTIES | Jointherapeutics S.r.l. | OLSON, ANDREA STEFFEL | 1693 | §103Other | Final Rejection | — | Pending | Nov 10, 2023 |
| 18558810 | NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF | UNIVERSITA' DI PISA (40%) | HERNANDEZ, JACKSON J | 1627 | §103§112 | Final Rejection | 29d | Pending | Nov 03, 2023 |
| 18493221 | USE OF A COMPOSITION COMPRISING MICROORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTYRIC ACID, FOLIC ACID OR NIACIN AND/OR DECREASE THE INTESTINAL PRODUCTION OF SUCCINIC ACID | Alfasigma S.p.A. | XU, QING | 1656 | §103 | Final Rejection | 63d | Pending | Oct 24, 2023 |
| 18552694 | DIGITAL INKJET PRINTING PRIMER FOR PLASTIC FILMS FOR FOOD PACKAGING | Goglio S.p.A. | HON, SOW FUN | 1782 | §103 | Non-Final OA | 40d | Pending | Sep 27, 2023 |
| 18546065 | SOLID COMPOSITION OF INDOCYANINE GREEN AND SODIUM FLUORESCEIN | Icrom Srl | LEWOCZKO, EVAN MICHAEL | 1612 | §103 | Final Rejection | 30d | Pending | Aug 10, 2023 |
| 18039204 | USE OF MULTI-SPECIFIC HUMAN ALBUMIN NANOPARTICLES DECORATED WITH ANTIBODY FRAGMENTS AND LOADED WITH CYTOTOXICS | Anbition S.r.l. | HAM, JIEUN | 1643 | §103§112DP | Non-Final OA | — | Pending | May 26, 2023 |
| 18246607 | RECOMBINANT YEAST FOR THE PRODUCTION OF OLIGOPEPTIDE | Lesaffre Et Compagnie | NOAKES, SUZANNE MARIE | 1656 | §103§112 | Final Rejection | 18d overdue | Pending | Mar 24, 2023 |
| 18022088 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BREAST CANCER | UNIVERSITA DEGLI STUDI DE GENOVA | DAHLIN, HEATHER RAQUEL | 1629 | §103Other | Final Rejection | — | Pending | Feb 17, 2023 |
| 18040525 | RETANNING AND FATLIQUORING COMPOSITIONS COMPRISING A HEMP OIL DERIVATIVE | UNIQUE S.R.L. | KHAN, AMINA S | 1761 | §103§112 | Final Rejection | 46d overdue | Pending | Feb 03, 2023 |
| 17999906 | AQUEOUS DESINFECTANT COMPOSITION FOR GLASSES | Unifarco S.p.A. | WISTNER, SARAH CLINKSCALES | 1616 | §112 | Final Rejection | 23d | Pending | Nov 25, 2022 |
| 17998534 | COMPOSITION COMPRISING METHYLFOLATE | Alfasigma S.p.A. | KASSA, TIGABU | 1619 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2022 |
| 17906477 | STABLE TOCOTRIENOL WITH IMMUNOMODULATING ACTION | Famafarm S.r.l. (50%) | ZILBERING, ASSAF | 1792 | §103§112 | Non-Final OA | — | Pending | Sep 16, 2022 |
| 17905646 | BLOOD PREPARATION USEFUL FOR WOUND HEALING AND TISSUE REGENERATION | Novystem S.p.A. | MELLER, MICHAEL V | 1655 | §103§112 | Final Rejection | 78d overdue | Pending | Sep 05, 2022 |
| 17904895 | HYBRID COSMETIC PRODUCT CONSISTING OF CREAMY COMPACT POWDER | Art Cosmetics S.R.L. | OLSEN, KAELEIGH ELIZABETH | 1619 | §103§112 | Non-Final OA | 78d overdue | Pending | Aug 24, 2022 |
| 17798218 | BIO-BASED BINDERS AND METHODS FOR PRODUCING SAME | Agroils Technologies S.p.A. | TOLIN, MICHAEL A | 1745 | §103§112 | Final Rejection | 13d | Pending | Aug 08, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial82.5% of resolved applications prosecuted by Silvia Salvadori, P.C. were allowed, across 1,055 applications in USPTO records.
3.92 office actions per allowed application on average.
56 pending office actions as of October 2026, for 49 clients, before 53 examiners in 38 art units.
